Zobrazeno 1 - 10
of 425
pro vyhledávání: '"J N, Fiessinger"'
Autor:
J.-N. Fiessinger
Publikováno v:
Bulletin de l'Académie Nationale de Médecine. 206:886-888
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::33cadd60081b47755c0298aeaf91cbe3
https://doi.org/10.1016/j.banm.2022.06.008
https://doi.org/10.1016/j.banm.2022.06.008
Autor:
J.-N. Fiessinger
Publikováno v:
Bulletin de l'Académie Nationale de Médecine. 203:1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5b833dbf2053e4b2f57437057df0f802
https://doi.org/10.1016/j.banm.2019.02.001
https://doi.org/10.1016/j.banm.2019.02.001
Publikováno v:
Thrombosis and Haemostasis. 79:897-901
SummaryBackground: Clinical trials have been performed to compare with standard heparin a once or a twice daily regimen of low-molecular-weight heparin but no direct comparison has been done between these two low-molecular-weight heparin regimens in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d43a77be1697df316120b87a64bdff33
https://doi.org/10.1055/s-0037-1615089
https://doi.org/10.1055/s-0037-1615089
Autor:
J N, Fiessinger, H, Bounameaux, M A, Cairols, D L, Clement, S, Coccheri, J P, Fletcher, U, Hoffmann, A G G, Turpie, R, Koppensteiner
Publikováno v:
Journal of Thrombosis and Haemostasis, Vol. 8, No 11 (2010) pp. 2369-2376
BACKGROUND: Terutroban is a selective prostaglandin endoperoxide (TP) receptor antagonist with antithrombotic, antivasoconstrictive and antiatherosclerotic properties and is currently in development for long-term cardiovascular secondary prevention.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5db2f1de2f375fd2194a596f3064b2b6
https://archive-ouverte.unige.ch/unige:20932
https://archive-ouverte.unige.ch/unige:20932
Autor:
H Bounameaux, J D Banga, E Bluhmki, S Coccheri, J N Fiessinger, W Haarmann, D Lockner, F Mahler, J Ninet, P A Schneider, A de Torrente, J van der Meer, and R Verhaeghe
Publikováno v:
Thrombosis and Haemostasis. 67:306-309
Thirty-two patients with acute, proximal-vein thrombosis were treated with heparin and alteplase (0.25 versus 0.5 mg/kg/24 h during 3-7 days) in a randomized, double-blind, multicenter, European (ETTT) trial. The treatment resulted in a decrease of t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ec3bd8e17381b18ec663245948afc465
https://doi.org/10.1055/s-0038-1648437
https://doi.org/10.1055/s-0038-1648437
Publikováno v:
Blood Coagulation & Fibrinolysis. 2:435-440
In human plasma, heparin cofactor II (HCII) is a thrombin inhibitor which displays similarities with antithrombin III (ATIII). As previously reported for hereditary ATIII deficiency, cases of recurrent thrombosis were reported in patients with heredi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d70a72abd338bab999293e008fc2e872
https://doi.org/10.1097/00001721-199106000-00005
https://doi.org/10.1097/00001721-199106000-00005
Autor:
Eric Clauser, P. Molho-Sabatier, J N Fiessinger, P de Moerloose, Sophie Gandrille, Martine Aiach, D Vidaud, R Caso, David A. Lane
Publikováno v:
Journal of Biological Chemistry. 265:18997-19001
An hereditary abnormal antithrombin III (ATIII Geneva) with defective heparin cofactor activity was characterized by DNA single strand amplification and subsequent direct sequencing. ATIII Geneva was found to have a G to A transition in Exon IIIa lea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e243c99e5447442c1d03bf01d6cb5a0e
https://doi.org/10.1016/s0021-9258(17)30614-2
https://doi.org/10.1016/s0021-9258(17)30614-2
Publikováno v:
Journal des maladies vasculaires. 32(4-5)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::5e809e0ea3e886d8795759b3cd6f35f9
https://pubmed.ncbi.nlm.nih.gov/17920221
https://pubmed.ncbi.nlm.nih.gov/17920221
Autor:
J N Fiessinger, M Azizi
Publikováno v:
La Revue de Médecine Interne. 19:697-699
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::289c34e641a17ffee3a1ad94c1b0f1bb
https://doi.org/10.1016/s0248-8663(98)80702-9
https://doi.org/10.1016/s0248-8663(98)80702-9
Autor:
Xavier Puéchal, J.-N. Fiessinger
Publikováno v:
Rheumatology (Oxford, England). 46(2)
Thromboangiitis obliterans (Buerger's disease)--a type of vasculitis in young, mostly male subjects--remains strangely linked to smoking, which determines its occurrence, progression and prognosis by currently unknown mechanisms. It affects the small
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05ac0988c5deca2513d00f7de92c7c12
https://pubmed.ncbi.nlm.nih.gov/17116654
https://pubmed.ncbi.nlm.nih.gov/17116654